Literature DB >> 35693070

Decoding the multidimensional signatures of resident and expanded natural killer cells generated from perinatal blood.

Leisheng Zhang1,2,3,4, Min Liu5, Baoquan Song6, Wenjing Miao6, Rucai Zhan2, Sijun Yang7, Zhihai Han7, Hui Cai1, Xianghong Xu8, Yixiao Zhao9, Zhongchao Han4,7,10, Tiankang Guo1, Jun Yao11, Qing Huang3.   

Abstract

Natural killer (NK) cells are lymphocytes and play a pivotal role in innate and adaptive immune responses against infections and malignancies. Longitudinal studies have indicated the feasibility of perinatal blood for large-scale NK cell generation, yet the systematic and detailed comparations of the signatures of resident and expanded NK cells (rNKs, eNKs) are largely obscure. Herein, we harvested rNKs from umbilical cord blood (rUC-NKs) and placental blood (rP-NKs) as well as the corresponding eNKs (eUC-NKs, eP-NKs). Furthermore, the biological properties and transcriptomic signatures including cellular subpopulations, cytotoxicity, gene expression profiling, genetic characteristics, signaling pathways and gene set-related biological process were investigated. The enriched rNKs and eNKs exhibited diversity in biomarker expression pattern, and eNKs with higher percentages of NKG2D+, NKG2A+, NKp44+ and NKp46+ subsets. rNKs or eNKs with different origins showed more similarities in transcriptomic signatures than those with the same origin. Our data revealed multifaceted similarities and differences of the indicated rNKs and pNKs both at the cellular and molecular levels. Our findings provide new references for further dissecting the efficacy and molecular mechanisms of rNKs and eNKs, which will collectively benefit the fundamental and translational studies of NK cell-based immunotherapy. AJCR
Copyright © 2022.

Entities:  

Keywords:  Perinatal blood; biological phenotype; expanded NK cells (eNKs); resident NK cells (rNKs); transcriptomic signatures

Year:  2022        PMID: 35693070      PMCID: PMC9185604     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  48 in total

1.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

Review 2.  Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials.

Authors:  Wade Chun-Wai Suen; Wayne Yuk-Wai Lee; Kam-Tong Leung; Xiao-Hua Pan; Gang Li
Journal:  Cancer Invest       Date:  2018-10-16       Impact factor: 2.176

Review 3.  New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles.

Authors:  M A Zaimy; N Saffarzadeh; A Mohammadi; H Pourghadamyari; P Izadi; A Sarli; L K Moghaddam; S R Paschepari; H Azizi; S Torkamandi; J Tavakkoly-Bazzaz
Journal:  Cancer Gene Ther       Date:  2017-06-02       Impact factor: 5.987

Review 4.  Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.

Authors:  Yuan Hu; Zhi-Gang Tian; Cai Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150

Review 5.  Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors.

Authors:  Vanderson Rocha; Eliane Gluckman
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

Review 6.  Natural killer cell-based immunotherapy for acute myeloid leukemia.

Authors:  Jing Xu; Ting Niu
Journal:  J Hematol Oncol       Date:  2020-12-07       Impact factor: 17.388

Review 7.  Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.

Authors:  Silvia Gaggero; Kristina Witt; Mattias Carlsten; Suman Mitra
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

Review 8.  CAR-NK cells for cancer immunotherapy: from bench to bedside.

Authors:  Leisheng Zhang; Yuan Meng; Xiaoming Feng; Zhongchao Han
Journal:  Biomark Res       Date:  2022-03-18

9.  Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy.

Authors:  Lin Kang; Vanessa Voskinarian-Berse; Eric Law; Tiffany Reddin; Mohit Bhatia; Alexandra Hariri; Yuhong Ning; David Dong; Timothy Maguire; Martin Yarmush; Wolfgang Hofgartner; Stewart Abbot; Xiaokui Zhang; Robert Hariri
Journal:  Front Immunol       Date:  2013-05-01       Impact factor: 7.561

10.  MSX2 Initiates and Accelerates Mesenchymal Stem/Stromal Cell Specification of hPSCs by Regulating TWIST1 and PRAME.

Authors:  Leisheng Zhang; Hongtao Wang; Cuicui Liu; Qingqing Wu; Pei Su; Dan Wu; Jiaojiao Guo; Wen Zhou; Yuanfu Xu; Lihong Shi; Jiaxi Zhou
Journal:  Stem Cell Reports       Date:  2018-07-19       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.